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CRP = C-reactive protein; HDL = high-density lipoprotein; LDL = low-density lipoprotein; MI = myocardial infarction; NYHA = New York Heart
Association; VLDL = very low-density lipoprotein.
4S = Scandinavian Simvastatin Survival Study; ELITE II = Losartan Heart Failure Survival Study; OPTIMAAL = Optimal Trial In Myocardial Infarction
with the Angiotensin II Antagonist Losartan.
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Coronary artery disease is the single most important cause of
heart failure, accounting for more than 50% of all new
occurrences [1]. Several factors are involved in the
progression to congestive heart failure, such as, the number
and extent of previous myocardial infarctions (MI),
neurohormonal activation, inflammatory reactions, patency of
the infarct-related artery, and remodelling of the myocardium.
In addition, clinical complications with arrhythmias, fever, and
metabolic disorders, may precipitate overt heart failure.
Treatment of heart failure may therefore target several
mechanisms, although, in most cases a recurrent MI is the
initiating event. In order to prevent further progression of heart
failure, it is most important to maintain adequate coronary
circulation, either by revascularisation procedures, prevention
of new lesions, or regression of established stenotic lesions.
Heart failure in the 4S Study
The effect of lipid reduction on the onset of heart failure has
recently been reported in the Scandinavian Simvastatin
Survival Study (4S) [2,3]. Four thousand, four hundred and
forty-four patients, with a previous history of coronary artery
disease and moderately elevated cholesterol, but without
signs or symptoms of heart failure, were randomised to
receive simvastatin (20–40 mg), or placebo. Treatment with
simvastatin reduced overall mortality from 12% to 8% (a
30% reduction). The reduction in mortality was almost
exclusively the result of a 42% reduction in coronary death.
Patients were followed up for more than four years. During
the follow-up, about 2% of patients presented evidence of
new heart failure — diagnosed as heart failure, pulmonary
oedema, acute pulmonary oedema, and lung fluid [3]. The
occurrence of heart failure was closely related to a recent MI.
Additionally, the rate of infarcts averaged less than ten per
3-month period, but this increased to 80 during the 3-month
period prior to the first occurrence of heart failure symptoms.
Further, there was a 20% reduction in the occurrence of
heart failure with simvastatin, compared to placebo. This was
in line with the reduction of recurrent MI (30%) observed
during the study.
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Abstract
Treatment to prevent progression of heart failure has been targeted to reverse the consequences of
heart failure and to a lesser extent the cause – the atherosclerotic plaque itself. Less than 50% of
patients with heart failure are treated with lipid intervention. Heart failure (New York Heart Association
[NYHA] functional classes I and II) is associated with an increase in low-density lipoproteins (LDL) and
triglycerides while high-density lipoproteins (HDL) is lowered. In NYHA class IV, cholesterol is reduced
due to depressed production in the liver. Although lipoproteins, especially LDL and HDL, may have
some protective effect in binding and neutralising endotoxins released from the intestine during terminal
heart failure, observational studies in patients with heart failure strongly suggest that lipid modification
with statins may reduce progression of heart failure as well as reducing heart failure mortality.
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The occurrence of heart failure in this group of patients was
characterized by mortality more than four times higher than in
patients who did not develop heart failure. In the patients with
heart failure, simvastatin reduced the risk of mortality by 19%
compared with 28% in those without heart failure [3]. However,
the important message was that the absolute reduction of death
was 6.1% in heart failure patients compared with 2.6% in
patients without heart failure. This difference in absolute risk
reduction was explained by the much higher mortality among
patients in the placebo group with heart failure, than those
without. Heart failure may therefore be a target condition for
treatment with statins in patients with coronary artery disease.
ELITE II
The hypothesis is further supported by a retrospective
analysis in chronic heart failure patients in the Losartan Heart
Failure Survival Study (ELITE II) [4]. In ELITE II, elderly
patients with heart failure were randomised to receive either
losartan or captopril [4]. No difference in mortality was
observed between the treatment groups. Of the 3152
patients enrolled, 11% were on a statin. The study
demonstrated that overall mortality was reduced from 17.6%
in patients without statins, to 10.6% among patients on a
statin (P < 0.003). No significant difference was seen in this
respect, between the losartan and captopril groups.
Effects of lipid lowering
The direct effect of lipid-lowering treatment is probably to stop
progression, or even to cause the regression, of coronary artery
stenosis and to stabilize coronary plaques, which in the long
term will reduce the recurrence of MI [2]. Furthermore, the
reduction of low-density lipoprotein (LDL) or very low-density
lipoprotein (VLDL), accounts for a reduction in the inflammatory
reaction observed during heart failure, which may confer
additional protection. C-reactive protein (CRP) — produced by
the liver in response to the inflammatory cytokines, IL-6, IL-1,
and TNFα — is associated with unfavourable effects on
endothelial function, plaque stability, and the myocardium [5,6].
Currently, 80–85% patients with coronary disease, but only
23–55% patients with heart failure, use lipid-lowering therapy
[7,8]. This may be because patients may be reluctant to add
another drug to their long list of heart failure medication.
However, more importantly, no prospective trials have yet been
carried out to test the efficacy and tolerance of lipid lowering in
heart failure patients. Further, the benefit of reducing
cholesterol in severe heart failure has recently been questioned
[9]. Reduction of coenzyme Q10 (ubiquinone) by statins, has
been assumed to depress the mitochondrial respiratory chain
mechanism, although there is no evidence that cellular levels
are critically reduced or of any clinical consequences.
Should lipids be lowered in end stage heart
failure?
Inflammatory cytokines are increased during heart failure, and
are assumed to be instrumental in the progression of end
stage heart failure to the terminal endpoint [10]. Endotoxin
(bacterial lipopolysaccharide), which is increased in end
stage heart failure is a very strong stimulator of inflammatory
cytokines. However, lipoproteins especially LDL and high-
density lipoprotein (HDL) cholesterol bind to endotoxin and
neutralise their effect [11,12]. It has therefore been
suggested that it is important to maintain elevated cholesterol
levels in end-stage heart failure [9]. This is supported by
observations of a negative relationship between cholesterol
and mortality in severe heart failure [13,14].
However, it is not known if this relationship is causal or just
an epiphenomenon and it is not clearly defined which
lipoprotein is the important one in this context. A recent study
of 132 patients listed for heart transplantation suggested that
the important lipoprotein is HDL, because low HDL was the
strongest predictor of worsening heart failure [12,15]. The
increase in HDL may therefore be a therapeutic goal in end
stage heart failure. Further, in severe heart failure the
combination of reduced liver flow and depressed cholesterol
synthesis may result in low levels of circulating cholesterol.
Most likely low total cholesterol is a consequence rather than
a cause of the poor prognosis. Cytokines and endotoxins
have been found to stimulate triglycerides and cholesterol
synthesis [16]. Conversely, statins have been found to
suppress the release of inflammatory cytokines [6,7] which
therefore may be additive to the direct and beneficial
lipomodulation by inhibition of hydroxymethyl glutaryl
coenzyme A (HMG CoA) reductase.
Answers from OPTIMAAL
The Optimal Trial In Myocardial infarction with Angiotensin
II Antagonist Losartan (OPTIMAAL) recently provided the
opportunity to examine the relationship between
lipoproteins and New York Heart Association (NYHA)
functional classes [17]. This trial included patients with
documented heart failure after an acute MI, and followed
them for more than two years. LDL cholesterol levels were
compared to Killip class at baseline, and to NYHA
classification during follow-up. After an acute MI, LDL was
lower in patients with Killip classes III and IV, than in
classes I and II. This is most likely due to the acute phase
reaction after acute MI. At six and twelve months the
pattern changed, and LDL was increased in proportion to
the severity of the heart failure.
At one year, LDL was higher in NYHA functional classes III
and IV, compared with functional classes I and II. In functional
class I, the LDL average was 2.78 mmol/L compared with
3.43 mmol/L, in class IV. At all time points HDL was lower in
functional class IV than in functional class I. Although the
study was not stratified for statin use, 55 % of the patients
used statins at discharge. It was found that patients treated
with statins had significantly fewer deaths at the one and
two-year follow-up points, compared to patients not treated
with statins.Current Controlled Trials in Cardiovascular Medicine    December 2001 Vol 2 No 6 Kjekshus
The same directional trend was shown for all modes of
deaths including sudden death, progression of congestive
heart failure, and fatal MI. When the patients were stratified
according to Killip class, the reduction in mortality with
simvastatin in class IV was significantly greater compared to
classes I and II. These results corroborate observations in
previous trials [4,5]. Thus there is strong evidence of benefit
from simvastatin treatment among patients with moderate
and severe heart failure.
Conclusion
The absolute reduction of mortality with lipid-lowering
treatment is greater in patients with heart failure, than without
heart failure. Evidence suggests that patients with severe
heart failure are the group that may improve most with statin
treatment. It is not known whether the effect of statins is
specifically related to LDL-lowering in patients with coronary
artery disease, or if it may also affect non-ischaemic
cardiomyopathy via endothelial and myocardial inflammatory
responses and increasing HDL cholesterol [18]. It would be
of major importance to our understanding of how statins
work, to conduct a study examining their effects in patients
with end stage heart failure, due to coronary artery disease
as well as nonischaemic cardiomyopathy.
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